Vireo Growth (VREOF) EBIT Margin (2020 - 2026)

Vireo Growth (VREOF) posted EBIT Margin of 8.47% for Q1 2026, up 588.13% sequentially from 1.74% in Q4 2025, and up 31.0% YoY from 6.47% in Q1 2025.

Vireo Growth (VREOF) EBIT Margin (2020 - 2026) Analysis & Trends

Vireo Growth has reported EBIT Margin for 7 years, with the latest figure at 8.47% in Q1 2026.

Quarterly EBIT Margin rose 31.0% year-over-year to 8.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.71% (down 912.0% YoY) and the FY2025 annual result came in at 0.39%, down 1404.0% from the prior year.
EBIT Margin improved to 8.47% in Q1 2026 per VREOF's latest filing, from 1.74% in the prior quarter.
Over five years, EBIT Margin peaked at 23.8% in Q3 2023 and troughed at 49.62% in Q1 2022.
A 5-year average of 3.75% and a median of 1.93% in 2023 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2022 and 2025: EBIT Margin surged 6416 bps in 2022, then plunged 2728 bps in 2025.
Over 5 years, EBIT Margin stood at 3.69% in 2022, then surged by 504 bps to 22.26% in 2023, then slumped by 115 bps to 3.36% in 2024, then soared by 48 bps to 1.74% in 2025, then jumped by 588 bps to 8.47% in 2026.
According to Business Quant data, EBIT Margin over the past three periods registered 8.47%, 1.74%, and 0.88% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Haleon	43.65 Bn	42.68 Bn	-	-
2	Teva Pharmaceutical Industries	43.09 Bn	39.44 Bn	2.15 Bn	-5.58%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	33.91%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	16.51%
5	United Therapeutics	22.11 Bn	19.45 Bn	683.80 Mn	42.23%
6	Viatris	18.77 Bn	17.88 Bn	1.46 Bn	0.17%
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	15.80%
8	Elanco Animal Health	12.07 Bn	11.54 Bn	798.00 Mn	18.13%
9	Dr Reddys Laboratories	10.09 Bn	9.93 Bn	-	-
10	Vireo Growth	492.35 Mn	350.05 Mn	95.30 Mn	-3.01%

Download Data